Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

2002 • 2,781 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

2003 • 1,564 citations

The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

1993 • 986 citations

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

1994 • 921 citations

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1

1999 • 803 citations

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.

1994 • 771 citations

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

1996 • 566 citations

Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues

1998 • 487 citations

An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.

1996 • 416 citations

Ex vivo identification, isolation and analysis of tumor-cytolytic T cells

2003 • 410 citations

Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?

2002 • 400 citations

A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3

1994 • 379 citations

Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells

2003 • 318 citations

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptidesin vivo

1996 • 308 citations

Immunizing Patients With Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma Antigens

1998 • 306 citations

Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression

1999 • 290 citations

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

2002 • 285 citations

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated antigens

1996 • 250 citations

Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

1997 • 215 citations

Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.

1996 • 215 citations

Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes

1993 • 195 citations

Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine

1999 • 188 citations

Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

1996 • 185 citations

Granulocyte‐macrophage–colony‐stimulating factor added to a multipeptide vaccine for resected Stage II melanoma

2002 • 173 citations

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report

2002 • 173 citations

Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine.

1996 • 150 citations

Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial

2002 • 150 citations

Prolonged Survival of Patients Receiving Active Immunotherapy With Canvaxin Therapeutic Polyvalent Vaccine After Complete Resection of Melanoma Metastatic to Regional Lymph Nodes

2002 • 148 citations

Sequence and expression pattern of the human MAGE2 gene

1994 • 144 citations

Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma

2000 • 131 citations

Modulation of Proteasomal Activity Required for the Generation of a Cytotoxic T Lymphocyte–defined Peptide Derived from the Tumor Antigen MAGE-3

1999 • 124 citations

Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma

2004 • 118 citations

Inability to Immunize Patients with Metastatic Melanoma Using Plasmid DNA Encoding the gp100 Melanoma-Melanocyte Antigen

2003 • 109 citations

T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.

2002 • 108 citations

CD1a in human cancers: a new role for an old molecule

2004 • 89 citations

Anti‐tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution

2003 • 85 citations

Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720)

1995 • 66 citations

Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.

1997 • 62 citations

The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.

2003 • 38 citations

On combining antineoplastic drugs with tumor vaccines

2003 • 27 citations

Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution

2003 • 18 citations

127. The multitest system for assay of delayed cutaneous hypersensitivity (DCH) to ubiquitous antigens

1978 • 11 citations

Therapy of Melanoma with Allogeneic Melanoma Lysates Alone or with Interferon-Alfa

2002 • 11 citations

HLA Class I DNA typing using sequence specific oligonucleotide probes (SSOP)

1997 • 8 citations

PHASE I TRIAL OF ADJUVANT VACCINATION WITH TYROSINASE PEPTIDES AND GM-CSF IN MELANOMA

1999 • 2 citations